2-[2-(3,4-dihydro-2H-quinolin-1-yl)ethyl]-3-oxo-2,3-dihydro-1H-isoindole-4-carboxylic acid amide | 1606996-01-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-[2-(3,4-dihydro-2H-quinolin-1-yl)ethyl]-3-oxo-2,3-dihydro-1H-isoindole-4-carboxylic acid amide
• 英文别名: 2-[2-(3,4-dihydroquinolin-1(2H)-yl)ethyl]-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide；2-[2-(3,4-dihydro-2H-quinolin-1-yl)ethyl]-3-oxo-1H-isoindole-4-carboxamide
• CAS: 1606996-01-3
• 化学式: C₂₀H₂₁N₃O₂
• 分子量: 335.406
• InChiKey: WGTJWDKKJAQXMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(2-氨基乙基)-1,2,3,4-四氢喹啉 在 盐酸 、 1-羟基-1H-苯并三唑铵盐 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.0h， 生成 2-[2-(3,4-dihydro-2H-quinolin-1-yl)ethyl]-3-oxo-2,3-dihydro-1H-isoindole-4-carboxylic acid amide
  参考文献：
  名称：

  Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy

  摘要：

  The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candidates in clinical testing that unselectively target both PARP-1 and its closest isoform PARP-2. The goal of our program was to find a PARP-1 selective inhibitor that would potentially mitigate toxicities arising from cross-inhibition of PARP-2. Thus, an HTS campaign on the proprietary Nerviano Medical Sciences (NMS) chemical collection, followed by SAR optimization, allowed us to discover 2-[1-4,4-difluorocyclohexyl)piperidin-4-yl] -6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118, 20by). NMS-P118 proved to be a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in vivo both as a single agent and in combination with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively. Cocrystal structures of 20by with both PARP-1 and PARP-2 catalytic domain proteins allowed rationalization of the observed selectivity.

  DOI：

  10.1021/acs.jmedchem.5b00680

文献信息

• [EN] 4-CARBOXAMIDO-ISOINDOLINONE DERIVATIVES AS SELECTIVE PARP-1 INHIBITORS<br/>[FR] DÉRIVÉS DE 4-CARBOXAMIDO-ISOINDOLINONE EN TANT QU'INHIBITEURS SÉLECTIFS DE PARP-1
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2014064149A1

  公开（公告）日：2014-05-01

  There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

  提供了替代的4-羧胺基异吲哚啉酮衍生物，可以选择性地抑制与PARP-2相比的聚(ADP-核糖)聚合酶PARP-1的活性。因此，本发明的化合物在治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病方面是有用的。本发明还提供了制备这些化合物的方法、包含这些化合物的药物组合物以及利用包含这些化合物的药物组合物治疗疾病的方法。
• 4-CARBOXAMIDO-ISOINDOLINONE DERIVATIVES AS SELECTIVE PARP-1 INHIBITORS
  申请人：NERVIANO MEDICAL SCIENCES S.R.L.

  公开号：US20150274662A1

  公开（公告）日：2015-10-01

  There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

  本发明提供了替代4-羧酰胺基异吲哚酮衍生物，其选择性地抑制聚(ADP-核糖)聚合酶PARP-1的活性，相对于聚(ADP-核糖)聚合酶PARP-2。因此，本发明的化合物可用于治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病。本发明还提供了制备这些化合物的方法、包含这些化合物的制药组合物以及利用包含这些化合物的制药组合物治疗疾病的方法。
• 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors
  申请人：NERVIANO MEDICAL SCIENCES S.r.l

  公开号：US10385018B2

  公开（公告）日：2019-08-20

  There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

  本发明提供了取代的 4-甲酰胺基异吲哚啉酮衍生物，相对于多（ADP-核糖）聚合酶 PARP-2 而言，它们能选择性地抑制多（ADP-核糖）聚合酶 PARP-1 的活性。因此，本发明的化合物可用于治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病。本发明还提供了制备这些化合物的方法、包含这些化合物的药物组合物，以及利用包含这些化合物的药物组合物治疗疾病的方法。
• Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy
  作者：Gianluca Papeo、Helena Posteri、Daniela Borghi、Alina A. Busel、Francesco Caprera、Elena Casale、Marina Ciomei、Alessandra Cirla、Emiliana Corti、Matteo D’Anello、Marina Fasolini、Barbara Forte、Arturo Galvani、Antonella Isacchi、Alexander Khvat、Mikhail Y. Krasavin、Rosita Lupi、Paolo Orsini、Rita Perego、Enrico Pesenti、Daniele Pezzetta、Sonia Rainoldi、Federico Riccardi-Sirtori、Alessandra Scolaro、Francesco Sola、Fabio Zuccotto、Eduard R. Felder、Daniele Donati、Alessia Montagnoli

  DOI：10.1021/acs.jmedchem.5b00680

  日期：2015.9.10

  The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candidates in clinical testing that unselectively target both PARP-1 and its closest isoform PARP-2. The goal of our program was to find a PARP-1 selective inhibitor that would potentially mitigate toxicities arising from cross-inhibition of PARP-2. Thus, an HTS campaign on the proprietary Nerviano Medical Sciences (NMS) chemical collection, followed by SAR optimization, allowed us to discover 2-[1-4,4-difluorocyclohexyl)piperidin-4-yl] -6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118, 20by). NMS-P118 proved to be a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in vivo both as a single agent and in combination with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively. Cocrystal structures of 20by with both PARP-1 and PARP-2 catalytic domain proteins allowed rationalization of the observed selectivity.